Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

Oncologist

Volumn 6, Issue 6, 2001, Pages 488-495

  Kozuch, Peter ^a   Grossbard, Michael L ^a   Barzdins, Atis ^a   Araneo, Miguel ^a   Robin, Abigail ^a   Frager, David ^a   Homel, Peter ^a   Marino, Jennifer ^a   Degregorio, Paola ^a   Bruckner, H W ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

5 fluorouracil leucovorin; Cisplatin; Gemcitabine; Irinotecan; Metastatic; Pancreatic cancer; Relapsed; Second line therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 18044362891     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-6-488     Document Type: Article

References (34)

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
2. Phase II trial of CPT-11 in patients with advanced pancreatic cancer: An EORTC early clinical trials group study
3. A late phase II study of irinotecan (CPT-11) in advanced pancreatic cancer
4. Multicenter phase II trial of first-line irinotecan and gemcitabine in patients with locally advanced or metastatic pancreatic cancer
5. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study
6. 5-Fluorouracil/cisplatin in the treatment of advanced pancreatic cancer
7. Gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A GISCAD phase II study
8. Phase I-II study of gemcitabine and weekly 48-hour continuous infusion high dose 5-fluorouracil in advanced exocrine pancreatic cancer
9. Phase II trial of gemcitabine with 24-hour infusion of 5-fluorouracil and folinic acid in patients with advanced pancreatic cancer
10. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: A clinical benefit-oriented phase II study
11. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
12. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
13. Drug interactions demonstrable in an ex vivo ATP assay system for gastrointestinal cancers
14. Combination of CPT-11 and 5-FU in colorectal cancer: Preclinical rationale and initial Phase I results
15. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines
16. Escalating dose irinotecan (CPT-11) immediately prior or after 5-fluorouracil 48 hours infusion + leucovorin (LV): Pharmacokinetic and pharmacodynamic interactions in chemotherapy-naive metastatic colorectal cancer patients
17. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
18. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
19. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
20. Gemcitabine-cisplatin: A schedule finding study
21. A phase I study of combination gemcitabine (gem) and irinotecan (CPT-11) in patients (pts) with refractory solid tumors
22. Inhibition by 5-fluorouracil of cisplatin (CDDP)-induced DNA interstrand cross-link removal as a mechanism for the sequence dependent synergy
23. Dysregulation of apoptosis in cancer
24. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage
25. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
26. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal cancer who were resistant to previous treatment with fluouropyrimidines
27. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
28. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
29. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation
30. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells
31. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
32. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucaronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
33. PEF-G (cisplatin, epirubicin, 5-fluorouracil continuous infusion, gemcitabine): A new combination in advanced pancreatic adenocarcinoma
34. Phase II study of a combination with leucovorin, 5-FU bolus and infusion, gemcitabine and oxaliplatin (FOLFU GEMOX regimen) in locally advanced and metastatic pancreatic carcinoma